Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
By C. Bokemeyer, I. Bondarenko, A. Makhson, J. Hartmann, J. Aparicio, F. D. De Braud, S. Donea, H. Ludwig, G. Schuch, C. Stroh and 3 more. Journal of Clinical Oncology, 2009
1,666 citations recorded by the source corpus.
Subfields: Biotechnology, Oncology
View Paper: https://www.semanticscholar.org/paper/6ae5469e84757751e8162b1a232d5db9698a1c24
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- A community computational challenge to predict the activity of pairs of compounds (2014, background): “Compound synergy can be measured by multiple endpoints, including reducing or delaying the development of resistance to treatment 3 (for instance by abrogating the emergence of resistant clones 4–6 ), improving overall survival 7,8 or lowering toxicity by decreasing individual compound dose 9 .”
- Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. (2010, background): “G13D-mutated).(19-22) The objective response rate in unselected patients was 10.”
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, result): “An improved RR and PFS with the combination of FOLFOX and cetuximab in (K)RAS WT patients has been reported in first-line treatment, but not consistently confirmed in first-line treatment with other oxaliplatin-based schedules, such as FLOX and CAPOX [41–44].”
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “Both cetuximab and panitumumab also increase the activity of the cytotoxic doublet FOLFOX in mCRC patients with RAS wild-type tumours [38, 45, 46, 48, 50, 183].”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (2011, neutral): “(2) FOLFIRI(6) [34, 35] ± bevacizumab [36, 37] (3) FOLFOX ± cetuximab/panitumumab [38, 39] (4) FOLFIRI ± cetuximab/panitumumab [40, 41] (5) 5-FU ? LV [42] ± bevacizumab [43, 44] or UFT ? LV [45] FOLFIRI bevacizumab* or CPT-11”
- A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. (2011, background): “S2, and Supplementary Table S2), again in agreement with clinical evidence (7-12).”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, neutral): “(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient ”
- Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. (2010, result): “In patients with MT KRAS tumors, there was no evidence of a benefit when panitumumab was added to FOLFIRI, and in contrast to what was observed in other studies with panitumumab or cetuximab in combination with oxaliplatin-based chemotherapy, there was no evidence of a detrimental effect in the MT K”
- Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. (2015, result): “However, it was reported that for patients with KRAS exon 2 tumor mutations, the addition of cetuximab to FOLFOX4 resulted in worse outcome compared with FOLFOX4 alone.(3,4) Similar findings were also reported from the PRIME (Panitumumab Randomized Trial in Combination With Chemotherapy for Metastat”